BioNTech and OncoC4 to partner for development and commercialisation of novel checkpoint antibody

M&A

BioNTech and OncoC4 have entered a strategic collaboration for the co-development and commercialisation of a novel checkpoint antibody for multiple solid tumor indications. BioNTech will receive an exclusive worldwide license from OncoC4 for its anti-CTLA-4 monoclonal antibody candidate, ONC-392.

The companies are expected to co-develop ONV-392 as either a monotherapy or in combination with anti-PD1 for the treatment of various solid tumour indications, with BioNTech also planning to combine ONC-392 with its other oncology candidates ‒ allowing the company to assess complementary treatments to increase the therapeutic impact of the drug.

OncoC4 will receive an upfront payment of $200m as well as being eligible for development, regulatory and commercial milestone payments and tiered royalties. The drug has already received Fast Track designation from the FDA as a monotherapy for immunotherapy-resistant non-small cell lung cancer (NSCLC).

It is expected that a phase 3 trial assessing ONC-392 will begin this year, although it is currently also being evaluated in a phase 2 trial as a combination therapy alongside pembrolizumab to treat platinum-resistant ovarian cancer.

Professor Ugur Sahin, MD, co-founder and CEO of BioNTech, commented: “Despite being a prime target for more than a decade, we believe that targeting CTLA-4 has not reached its full potential in cancer immunotherapy. The data presented by OncoC4 on its ONC-392 antibody indicate a differentiated safety profile and encouraging clinical activity in various types of tumours. We believe that this antibody is a valuable addition to our immuno-oncology portfolio, whether used alone or in combination with our personalised immunotherapies.”

Yang Liu, PhD, co-founder, CEO and CSO of OncoC4, added: “Because of its specific mechanism of action, we believe ONC-392 has the potential to broaden the reach of CTLA- 4-targtting immunotherapy. We very much look forward to working hand-in-hand with BioNTech in developing ONC-392 for cancer indications with unmet medical needs.”

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead sciences has announced the acquisition of all outstanding shares of XinThera, a privately owned biotech company based in San Diego, US. This acquisition aims to strengthen Gilead’s clinical development pipeline through the addition of XinThera’s oncology and inflammation assets.

GSK enters into £1.6bn deal to acquire Bellus Health

UK-based GSK has announced its plans to acquire Bellus Health, a Canadian late-stage biopharmaceutical company that focuses on treatments for refractory chronic cough (RCC). The acquisition will give GSK access to Camlipixant, Bellus’ first-in-class treatment for RCC.

Sobi acquires CTI BioPharma Corporation for $1.7bn

Swedish Orphan Biovitrum (Sobi) has announced that it had entered into a ‘plan of merger’ with CTI Biopharma Corp (CTI), a biopharmaceutical company focused on blood-related cancers and rare diseases, by means of a tender offer valued at $1.7bn.

Pfizer signs $43bn deal to buy Seagen

Pharma giant Pfizer has signed a definitive merger agreement valued at $43bn to buy biotech firm Seagen. US-based Seagen discovers, develops and commercialises cancer medicines through pioneering antibody-drug conjugates (ADCs) technology. It currently has four approved medicines in its portfolio, including three ADCs: adcetris (brentuximab vedotin) for lymphoma; padcev (enfortumab vedotin) for bladder cancers; and tivdak (tisotumab vedotin) for cervical cancer.

Théa Open Innovation & Galimedix announce partnership for development & commercialisation of GAL-101

Théa Open Innovation (TOI) and Galimedix have announced that they have signed a licensing agreement granting TOI exclusive rights for the development and commercialisation of GAL-101, Galimedix’s treatment for dry age-related macular degeneration (AMD), glaucoma and other ophthalmic indications with high unmet medical need, in Europe, the Americas, the Middle East and Africa.

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

GSK enters into £1.6bn deal to acquire Bellus Health

Sobi acquires CTI BioPharma Corporation for $1.7bn

Pfizer signs $43bn deal to buy Seagen

Théa Open Innovation & Galimedix announce partnership for development & commercialisation of GAL-101

Pharmafocus

Categories

Social Footprints